Clinical reports and literature documenting neonatal abstinence syndrome (NAS), maternal dependence, and withdrawal associated with prenatal kratom exposure.
Lead crosses the placenta. It has been detected in fetal tissue and is associated with spontaneous abortion, low birth weight, preterm delivery, and impaired neurodevelopment. There is no known safe level of lead exposure during pregnancy.
Independent laboratory analysis of commercial kratom products has consistently found measurable lead contamination:
At roughly 1 µg/g lead, a single 5‑gram dose delivers about 5 micrograms of lead. Multiple doses per day turn a "trace" lab finding into repeated ingestion — and for a pregnant woman, repeated placental transfer to the developing fetus. Every published neonatal case report documenting kratom withdrawal is also a case of repeated fetal lead exposure during critical windows of brain and organ development.
The FDA has warned that kratom products contain lead and nickel at levels not considered safe for human consumption, and that heavy kratom users may be exposed to levels many times greater than safe daily exposure.Import Alert 54‑15 (updated February 2025) allows detention of all kratom‑containing dietary supplements entering U.S. commerce.
Newborn with tremors, hypertonia, high‑pitched cry required morphine then clonidine. Small for gestational age. Kratom's harm to neonates justifies control.
Read Case →Mother used 18‑20 g kratom daily throughout pregnancy; infant developed severe NAS requiring IV morphine. Kratom crosses placenta and causes opioid‑type withdrawal.
Read Case →Infant born to chronic kratom user needed oral morphine for 11 days. Standard toxicology missed kratom. Prenatal exposure causes serious withdrawal.
Read Case →Neonate with withdrawal despite negative urine screen; clonidine required. Kratom produces clear NAS, similar to opioids.
Read Case →Review of 12 exposed infants: >80% developed NAS, 70% required morphine. Intrauterine growth restriction noted. Kratom use during pregnancy endangers fetal development.
Read Review →Up to 80% of pregnant kratom users take it to manage opioid withdrawal; neonates exhibit NAS requiring morphine or clonidine. Kratom poses serious perinatal risks.
Read Review →FDA warns that kratom is associated with neonatal abstinence syndrome and advises against use during pregnancy.
Read Statement →Case report noting maternal kratom dependence; highlights need for screening before naltrexone or other interventions.
Read Case →15‑year‑old ingested 45 capsules as suicide attempt. Pediatric exposure risk extends beyond neonatal period.
Read Case →Kratom use during pregnancy has been associated with neonatal abstinence syndrome (NAS) requiring pharmacologic treatment. Symptoms typically appear within 6–96 hours after birth and include jitteriness, irritability, hypertonia, tremors, feeding difficulties, vomiting, high‑pitched cry, and dyspnea. Standard urine toxicology screens do not detect mitragynine or 7‑OH, potentially delaying diagnosis. Treatment of NAS has included morphine, clonidine, and supportive care. Maternal dependence can complicate prenatal care and delivery. The FDA advises against kratom use during pregnancy and breastfeeding due to risks of neonatal withdrawal and lack of safety data.
Obstetric and pediatric clinicians should maintain a high index of suspicion for prenatal kratom exposure when evaluating infants with withdrawal symptoms unexplained by other substances. Routine toxicology panels should be supplemented with specific testing for mitragynine when clinically indicated.
